HOOKIPA Pharma Elects New Directors, Files Exhibits

TL;DR

HOOKIPA adds 2 directors, files financials & exhibits. Board shakeup incoming?

AI Summary

HOOKIPA Pharma Inc. announced on August 27, 2024, a change in its board of directors, with the election of Dr. Jonathan Lim and Dr. David Sidransky as Class II directors. The company also disclosed compensatory arrangements for certain officers and provided a Regulation FD disclosure. Financial statements and exhibits were filed as part of this report.

Why It Matters

Changes in board composition can signal shifts in company strategy or governance, while the filing of financial statements and exhibits provides crucial updates for investors.

Risk Assessment

Risk Level: medium — Board changes and regulatory filings can introduce uncertainty or signal strategic shifts that may impact the company's future performance.

Key Players & Entities

• HOOKIPA Pharma Inc. (company) — Registrant
• Dr. Jonathan Lim (person) — Elected Class II Director
• Dr. David Sidransky (person) — Elected Class II Director
• August 27, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — e on which registered Common Stock, $0.0001 par value per share HOOK The Nasdaq

Filing Documents

• tm2423083d1_8k.htm (8-K) — 32KB
• tm2423083d1_ex99-1.htm (EX-99.1) — 6KB
• tm2423083d1_ex99-1img001.jpg (GRAPHIC) — 14KB
• 0001104659-24-095236.txt ( ) — 232KB
• hook-20240827.xsd (EX-101.SCH) — 3KB
• hook-20240827_lab.xml (EX-101.LAB) — 33KB
• hook-20240827_pre.xml (EX-101.PRE) — 22KB
• tm2423083d1_8k_htm.xml (XML) — 4KB

02 Departure of Directors or Certain

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 27, 2024, Jan van de Winkel, Ph.D., notified HOOKIPA Pharma Inc. (the "Company") of his resignation as a director of the Company, effective as of August 30, 2024 at 12:00 p.m. Eastern Time (the "Effective Time"). Dr. van de Winkel's resignation was not the result of a disagreement with the Company on any matter relating to the Company's operations, policies or practices. On August 27, 2024, Timothy Reilly, Ph.D., notified the Company of his resignation as a director of the Company, effective as of the Effective Time. Dr. Reilly's resignation was not the result of a disagreement with the Company on any matter relating to the Company's operations, policies or practices. In connection with the resignations of Dr. van de Winkel and Dr. Reilly, the Company's board of directors (the "Board") appointed Julie O'Neill to serve as non-executive chair of the Board, effective as of the Effective Time. Board Reclassification As of the Effective Time, the authorized size of the Board will be five members. Following notification of the resignations of Drs. van de Winkel and Reilly, the Board reclassified the members of the Board into three classes of nearly equal size, effective as of the Effective Time. To effect this change, Ms. O'Neill was removed as a Class III director and was immediately reappointed as a Class I director, to stand for re-election at the 2026 Annual Meeting of Stockholders. Reconstitution of Board Committees In connection with the reclassification of the Board as set forth above, the Board approved the reconstitution of the committees of the Board as set forth below: The Audit Committee will consist of Sean Cassidy (Chair), David Kaufman, M.D., Ph.D. and Julie O'Neill. The Compensation Committee will consist of Julie O'Neill (Chair) and Sean Cassidy. The Nominating and Corporate G

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On August 30, 2024, the Company issued a press release announcing the resignations of Dr. van de Winkel and Dr. Reilly described in Item 5.02 of this Current Report on Form 8-K, a copy of which is attached as Exhibit 99.1 and incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press Release, dated August 30, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 30, 2024 HOOKIPA Pharma Inc. By: /s/ Malte Peters Name: Malte Peters Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR